ArticleHaematologica2020
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.Journal of blood medicine · 2026Trial
- US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group.Acta haematologica · 2024Trial
- Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.Blood advances · 2023Trial
- Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.Annals of hematology · 2023Trial
- The Proteasome Safeguards Red Blood Cell Integrity During Storage and After Transfusion.Antioxidants (Basel, Switzerland) · 2026Article
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- Impact of Transfusion Dependence on Clinical and Economic Burden in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Study.Journal of blood medicine · 2026Article
- Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS.Blood cancer journal · 2025Article
- Updates in low/intermediate-risk MDS.Hematology. American Society of Hematology. Education Program · 2025Review
- Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.JCO clinical cancer informatics · 2025Article
- Fat Fraction and Iron Concentration in Lumbar Vertebral Bone Marrow in the UK Biobank.Obesity science & practice · 2025Article
- Review
- Advances and challenges in the treatment of myelodysplastic syndromes.Experimental hematology & oncology · 2025Review
- Article
- Long-Term Experience with Luspatercept in Relapsed/Refractory Myelodysplastic Neoplasms: A Chinese Real-World Study.Advances in therapy · 2025Article
- Treatment of high-risk myelodysplastic syndromes.Haematologica · 2025Review
- MDS patient registries - achievements and challenges.Annals of hematology · 2024Review
- Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.Current treatment options in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 17 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly intervals from newly diagnosed lower-risk myelodysplastic syndromes patients in 16 European countries and Israel. Data on the transfusion dose density - the cumulative dose received at the end of each interval divided by the time since the beginning of the interval in which the first transfusion was received - were analyzed using proportional hazards regression with time-varying co-variates, with death and progression to higher-risk MDS/acute myeloid leukemia as events. Of the 1,267 patients included in the analyses, 317 died without progression; in 162 patients the disease had progressed. PFS was significantly associated with age, EQ-5D index, baseline World Health Organization classification, bone marrow blast count, cytogenetic risk category, number of cytopenias, and country. Transfusion dose density was inversely associated with PFS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.